{"doi":"10.1002/ana.24558","title":"Tranexamic acid–associated seizures: Causes and treatment","abstract":"<jats:p>Antifibrinolytic drugs are routinely used worldwide to reduce the bleeding that results from a wide range of hemorrhagic conditions. The most commonly used antifibrinolytic drug, tranexamic acid, is associated with an increased incidence of postoperative seizures. The reported increase in the frequency of seizures is alarming, as these events are associated with adverse neurological outcomes, longer hospital stays, and increased in‐hospital mortality. However, many clinicians are unaware that tranexamic acid causes seizures. The goal of this review is to summarize the incidence, risk factors, and clinical features of these seizures. This review also highlights several clinical and preclinical studies that offer mechanistic insights into the potential causes of and treatments for tranexamic acid–associated seizures. This review will aid the medical community by increasing awareness about tranexamic acid–associated seizures and by translating scientific findings into therapeutic interventions for patients. ANN NEUROL 2016;79:18–26</jats:p>","journal":"Annals of Neurology","year":2016,"id":655030,"datarank":0.844681767273205,"base_score":5.631211781821365,"endowment":5.631211781821365,"self_citation_contribution":0.844681767273205,"citation_network_contribution":0.0,"self_endowment_contribution":0.844681767273205,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":278,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1709683,"name":"Dian‐Shi Wang","orcid":null,"position":1,"is_corresponding":false},{"id":327528,"name":"Paul D. Whissell","orcid":null,"position":2,"is_corresponding":false},{"id":1709684,"name":"Sinziana Avramescu","orcid":null,"position":3,"is_corresponding":false},{"id":547135,"name":"C. David Mazer","orcid":"0000-0003-2566-4308","position":4,"is_corresponding":false},{"id":1709685,"name":"Beverley A. Orser","orcid":null,"position":5,"is_corresponding":false},{"id":327520,"name":"Irene Lecker","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Tranexamic acid–associated seizures: Causes and treatment","abstract":"<jats:p>Antifibrinolytic drugs are routinely used worldwide to reduce the bleeding that results from a wide range of hemorrhagic conditions. The most commonly used antifibrinolytic drug, tranexamic acid, is associated with an increased incidence of postoperative seizures. The reported increase in the frequency of seizures is alarming, as these events are associated with adverse neurological outcomes, longer hospital stays, and increased in‐hospital mortality. However, many clinicians are unaware that tranexamic acid causes seizures. The goal of this review is to summarize the incidence, risk factors, and clinical features of these seizures. This review also highlights several clinical and preclinical studies that offer mechanistic insights into the potential causes of and treatments for tranexamic acid–associated seizures. This review will aid the medical community by increasing awareness about tranexamic acid–associated seizures and by translating scientific findings into therapeutic interventions for patients. ANN NEUROL 2016;79:18–26</jats:p>","is_dataset_classified":null,"base_score":5.631211781821365,"endowment":5.631211781821365,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"26580862","pmcid":"PMC4738442","openalex_id":"https://openalex.org/W2174657578","authors":[],"funders":[{"funder_name":"Canadian Institutes of Health Research","grant_id":"MOP-79428","title":null},{"funder_name":"Canadian Institutes of Health Research","grant_id":"MOP-38028","title":null},{"funder_name":"Canadian Institutes of Health Research","grant_id":"unidentified","title":"unidentified"},{"funder_name":"CIHR Frederick Banting &amp; Charles Best Doctoral Award","grant_id":"","title":null},{"funder_name":"CIHR Fellowship, a Clinician Scientist Transition Award","grant_id":"","title":null},{"funder_name":"Canadian Institute of Health Research (CIHR)","grant_id":"","title":null},{"funder_name":"Department of Anesthesia, University of Toronto","grant_id":"","title":null}],"total_grants":7,"fwci":6.7697,"citation_percentile":0.98461538,"influential_citations":0,"citation_trend":[{"year":2012,"count":1},{"year":2016,"count":6},{"year":2017,"count":21},{"year":2018,"count":19},{"year":2019,"count":23},{"year":2020,"count":25},{"year":2021,"count":42},{"year":2022,"count":29},{"year":2023,"count":44},{"year":2024,"count":30},{"year":2025,"count":22},{"year":2026,"count":15}],"oa_status":"hybrid","license":"cc-by-nc-nd","oa_locations":[{"url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ana.24558","host_type":"journal"},{"url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ana.24558","host_type":"publisher"},{"url":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fana.24558","host_type":"publisher"},{"url":"https://onlinelibrary.wiley.com/doi/pdf/10.1002/ana.24558","host_type":"publisher"},{"url":"https://onlinelibrary.wiley.com/doi/full-xml/10.1002/ana.24558","host_type":"publisher"},{"url":"https://doi.org/10.1002/ana.24558","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/26580862","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/4738442","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC4738442","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC4738442?pdf=render","host_type":"Europe_PMC"},{"url":"http://dx.doi.org/10.1002/ana.24558","host_type":""},{"url":"https://dx.doi.org/10.1002/ana.24558","host_type":""}],"fields_of_study":["Blood transfusion and management","Epilepsy research and treatment","Blood groups and transfusion","03 medical and health sciences","0302 clinical medicine","Animals","Antifibrinolytic Agents","Humans","Seizures","Tranexamic Acid"],"mesh_terms":["Animals","Antifibrinolytic Agents","Humans","Seizures","Tranexamic Acid"],"keywords":["Tranexamic acid","Medicine","Anesthesia","Epilepsy","Surgery","Psychiatry","Blood loss","Seizures","Animals","Humans","Review","Antifibrinolytic Agents"],"sdg_mappings":[{"sdg_number":3,"sdg_label":"3. Good health"},{"sdg_number":14,"sdg_label":"14. Life underwater"},{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-11T09:22:51.169280Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}